Artivion (NYSE:AORT) Price Target Raised to $25.00

Artivion (NYSE:AORT) had its target price hoisted by investment analysts at Stifel Nicolaus from $22.00 to $25.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 18.65% from the stock’s current price.

Separately, Needham & Company LLC upped their price target on Artivion from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday.

Artivion Trading Up 0.7 %

Shares of AORT stock opened at $21.07 on Tuesday. Artivion has a 1-year low of $12.16 and a 1-year high of $21.90. The firm’s 50-day simple moving average is $20.40 and its 200-day simple moving average is $18.06. The firm has a market cap of $868.08 million, a P/E ratio of -28.09 and a beta of 1.66. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.85 and a quick ratio of 3.43.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Monday, May 6th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.04. Artivion had a negative net margin of 8.67% and a positive return on equity of 3.02%. During the same quarter in the prior year, the company earned $0.02 EPS. As a group, equities analysts forecast that Artivion will post 0.26 EPS for the current year.

Insider Activity at Artivion

In other Artivion news, CAO Amy Horton sold 1,695 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $18.86, for a total transaction of $31,967.70. Following the transaction, the chief accounting officer now owns 122,345 shares in the company, valued at $2,307,426.70. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Artivion news, insider John E. Davis sold 2,556 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $18.86, for a total value of $48,206.16. Following the completion of the transaction, the insider now directly owns 128,177 shares of the company’s stock, valued at approximately $2,417,418.22. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Amy Horton sold 1,695 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $18.86, for a total value of $31,967.70. Following the completion of the transaction, the chief accounting officer now owns 122,345 shares in the company, valued at approximately $2,307,426.70. The disclosure for this sale can be found here. In the last three months, insiders sold 149,952 shares of company stock worth $2,891,627. Corporate insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On Artivion

Hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC raised its position in shares of Artivion by 38.6% in the 1st quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock valued at $38,000 after purchasing an additional 505 shares in the last quarter. Register Financial Advisors LLC bought a new position in Artivion during the 1st quarter valued at $114,000. Allspring Global Investments Holdings LLC grew its holdings in Artivion by 291.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock worth $118,000 after acquiring an additional 4,154 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Artivion by 97.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,322 shares of the company’s stock worth $126,000 after purchasing an additional 4,099 shares during the last quarter. Finally, Silverleafe Capital Partners LLC acquired a new stake in shares of Artivion in the 3rd quarter valued at about $152,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.